Paradoxical benzodiazepine response: A rationale for bumetanide in neurodevelopmental disorders?

Pediatrics

Volumn 136, Issue 2, 2015, Pages e539-e543

  Bruining, Hilgo ^a,b   Passtoors, Laurien ^b   Goriounova, Natalia ^c   Jansen, Floor ^b   Hakvoort, Britt ^d   De Jonge, Maretha ^b   Poil, Simon Shlomo ^e  

^a Departments of Translational Neuroscience   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Turing Center for Living Systems CENTURI Aix Marseille University   (France)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BUMETANIDE; CLOBAZAM; LAMOTRIGINE; OXCARBAZEPINE; VALPROIC ACID; BENZODIAZEPINE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ARTICLE; AUTISM; BEHAVIOR DISORDER; CASE REPORT; CHILD; CHROMOSOME DUPLICATION; COGNITION; COPY NUMBER VARIATION; CORTICAL DYSPLASIA; DEVELOPMENTAL DISORDER; ELECTROENCEPHALOGRAPHY; EMOTIONAL DISORDER; FEMALE; FOCAL EPILEPSY; HUMAN; LANGUAGE DELAY; LEARNING DISORDER; MEMORY DISORDER; MUSCLE RIGIDITY; NEURODEVELOPMENTAL DISORDER; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARADOXICAL DRUG REACTION; PRIORITY JOURNAL; SCHOOL CHILD; SEIZURE; COMPLICATION; DEVELOPMENTAL DISABILITIES; NERVOUS SYSTEM DISEASES; TREATMENT OUTCOME;

BENZODIAZEPINES; BUMETANIDE; CHILD; DEVELOPMENTAL DISABILITIES; FEMALE; HUMANS; NERVOUS SYSTEM DISEASES; TREATMENT OUTCOME;

EID: 84938829278     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-4133     Document Type: Article

References (36)

1. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994;24(5):659-685
2. Burnside RD, Pasion R, Mikhail FM, et al. Microdeletion/microduplication of proximal 15q11.2 between BP1 and BP2: a susceptibility region for neurological dysfunction including developmental and language delay. Hum Genet. 2011;130(4): 517-528
3. Mancuso CE, Tanzi MG, Gabay M. Paradoxical reactions to benzodiazepines: literature review and treatment options. Pharmacotherapy. 2004;24(9):1177-1185
4. Marrosu F, Marrosu G, Rachel MG, Biggio G. Paradoxical reactions elicited by diazepam in children with classic autism. Funct Neurol. 1987;2(3):355-361
5. Ben-Ari Y, Khalilov I, Kahle KT, Cherubini E. The GABA excitatory/inhibitory shift in brain maturation and neurological disorders. Neuroscientist. 2012;18(5):467-486
6. Lemonnier E, Degrez C, Phelep M, et al. A randomised controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatr. 2012;2:e202
7. Dunn W. The Sensory Profile: User's Manual. San Antonio, TX: The Psychological Corporation; 1999
8. Lam KS, Aman MG. The Repetitive Behavior Scale-Revised: independent validation in individuals with autism spectrum disorders. J Autism Dev Disord. 2007;37(5):855-866
9. De Sonneville LMJ. Amsterdam Neuropsychological Tasks: a computer aided assessment programme. In: Den Brinker PJ, Beek AN, Brand FJ, Mulder LJM, eds. Cognitive Ergonomics, Clinical Assessment and Computer Assisted Learning: Computers in Psychology. Lisse, Netherlands: Swets and Zeitlinger; 1999:187-203
10. Meyers J, Meyers K. Rey Complex Figure Test and Recognition Trial. FL: Psychological Assessment Resources; 1995
11. van den Burg W, Kingma A. Performance of 225 Dutch school children on Rey's Auditory Verbal Learning Test (AVLT): parallel test-retest reliabilities with an interval of 3 months and normative data. Arch Clin Neuropsychol. 1999;14(6):545-559
12. Wilhelm P, Swaab H, Serlier-Van den Bergh AHML, K.B. VdH. Rey Visual Design Learning Test (RVDLT). Nederlandse bewerking. Nederland: Bohn Stafleu van Loghum; 2011
13. Smidts D, Huizinga M. BRIEF Executieve Functies Gedragsvragenlijst Handleiding. Dutch Translation of the Behavior Rating Inventory of Executive Function. Amsterdam, Netherlands: Hogrefe; 2009
14. Wechsler D. Wechsler Preschool and Primary Scale of Intelligence-Revised. New York, NY: Psychological Corporation; 1989
15. Poil SS, de Haan W, van der Flier WM, Mansvelder HD, Scheltens P, Linkenkaer-Hansen K. Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage. Front Aging Neurosci. 2013;5:58
16. van der Leij A, van Bergen E, van Zuijen T, de Jong P, Maurits N, Maassen B. Precursors of developmental dyslexia: an overview of the longitudinal Dutch Dyslexia Programme study. Dyslexia. 2013;19(4):191-213
17. Tyzio R, Nardou R, Ferrari DC, et al. Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring. Science. 2014;343(6171):675-679
18. Nardou R, Yamamoto S, Bhar A, Burnashev N, Ben-Ari Y, Khalilov I. Phenobarbital but not diazepam reduces AMPA/kainate receptor mediated currents and exerts opposite actions on initial seizures in the neonatal rat hippocampus. Front Cell Neurosci. 2011;5:16
19. Nardou R, Yamamoto S, Chazal G, et al. Neuronal chloride accumulation and excitatory GABA underlie aggravation of neonatal epileptiform activities by phenobarbital. Brain. 2011;134(pt 4):987-1002
20. Berman ME, Jones GD, McCloskey MS. The effects of diazepam on human selfaggressive behavior. Psychopharmacology (Berl). 2005;178(1):100-106
21. Bramness JG, Skurtveit S, Mørland J. Flunitrazepam: psychomotor impairment, agitation and paradoxical reactions. Forensic Sci Int. 2006; 159(2-3):83-91
22. Cole JO, Kando JC. Adverse behavioral events reported in patients taking alprazolam and other benzodiazepines. J Clin Psychiatry. 1993;54(suppl):49-61; discussion 62-63
23. Gioia GA, Isquith PK, Retzlaff PD, Espy KA. Confirmatory factor analysis of the Behavior Rating Inventory of Executive Function (BRIEF) in a clinical sample. Child Neuropsychol. 2002;8(4):249-257
24. Perlwitz R, Grimmberger E, Schmidtsdorf R. Immediate effect of intravenous clonazepam on the EEG [in German]. Psychiatr Neurol Med Psychol (Leipz). 1980;32(6):338-344
25. Cornew L, Roberts TP, Blaskey L, Edgar JC. Resting-state oscillatory activity in autism spectrum disorders. J Autism Dev Disord. 2012;42(9):1884-1894
26. Wang J, Barstein J, Ethridge LE, Mosconi MW, Takarae Y, Sweeney JA. Resting state EEG abnormalities in autism spectrum disorders. J Neurodev Disord. 2013;5(1):24
27. Palva S, Palva JM. New vistas for alphafrequency band oscillations. Trends Neurosci. 2007;30(4):150-158
28. Ahveninen J, Lin FH, Kivisaari R, et al. MRI-constrained spectral imaging of benzodiazepine modulation of spontaneous neuromagnetic activity in human cortex. Neuroimage. 2007;35(2):577-582
29. Hall SD, Barnes GR, Furlong PL, Seri S, Hillebrand A. Neuronal network pharmacodynamics of GABAergic modulation in the human cortex determined using pharmacomagnetoencephalography. Hum Brain Mapp. 2010;31(4):581-594
30. Beracochea D. Anterograde and retrograde effects of benzodiazepines on memory. ScientificWorldJournal. 2006;6:1460-1465
31. Lozano-Soldevilla D, ter Huurne N, Cools R, Jensen O. GABAergic modulation of visual gamma and alpha oscillations and its consequences for working memory performance. Curr Biol. 2014;24(24): 2878-2887
32. Savic MM, Obradovic DI, Ugresic ND, Bokonjic DR. Memory effects of benzodiazepines: memory stages and types versus binding-site subtypes. Neural Plast. 2005;12(4):289-298
33. Eftekhari S, Mehvari Habibabadi J, Najafi Ziarani M, et al. Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy. Epilepsia. 2013; 54(1):e9-e12
34. Huberfeld G, Wittner L, Clemenceau S, et al. Perturbed chloride homeostasis and GABAergic signaling in human temporal lobe epilepsy. J Neurosci. 2007; 27(37):9866-9873
35. Shimizu-Okabe C, Tanaka M, Matsuda K, et al. KCC2 was downregulated in small neurons localized in epileptogenic human focal cortical dysplasia. Epilepsy Res. 2011;93(2-3):177-184
36. Talos DM, Sun H, Kosaras B, et al. Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia. Ann Neurol. 2012; 71(4):539-551